- Home
- TALK vs XERS Comparison
TALK vs XERS Comparison
Compare TALK & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TALK
- XERS
- Stock Information
- Founded
- TALK 2012
- XERS 2005
- Country
- TALK United States
- XERS United States
- Employees
- TALK N/A
- XERS N/A
- Industry
- TALK Medical/Nursing Services
- XERS Biotechnology: Pharmaceutical Preparations
- Sector
- TALK Health Care
- XERS Health Care
- Exchange
- TALK Nasdaq
- XERS Nasdaq
- Market Cap
- TALK 534.6M
- XERS 500.2M
- IPO Year
- TALK N/A
- XERS 2018
- Fundamental
- Price
- TALK $3.02
- XERS $3.20
- Analyst Decision
- TALK Buy
- XERS Buy
- Analyst Count
- TALK 5
- XERS 3
- Target Price
- TALK $4.38
- XERS $4.87
- AVG Volume (30 Days)
- TALK 1.2M
- XERS 1.4M
- Earning Date
- TALK 02-20-2025
- XERS 03-05-2025
- Dividend Yield
- TALK N/A
- XERS N/A
- EPS Growth
- TALK N/A
- XERS N/A
- EPS
- TALK N/A
- XERS N/A
- Revenue
- TALK $181,291,000.00
- XERS $187,361,000.00
- Revenue This Year
- TALK $28.22
- XERS $24.27
- Revenue Next Year
- TALK $23.48
- XERS $18.57
- P/E Ratio
- TALK N/A
- XERS N/A
- Revenue Growth
- TALK 31.50
- XERS 22.72
- 52 Week Low
- TALK $1.60
- XERS $1.69
- 52 Week High
- TALK $3.92
- XERS $3.87
- Technical
- Relative Strength Index (RSI)
- TALK 46.07
- XERS 41.99
- Support Level
- TALK $2.77
- XERS $3.14
- Resistance Level
- TALK $3.11
- XERS $3.60
- Average True Range (ATR)
- TALK 0.15
- XERS 0.17
- MACD
- TALK -0.01
- XERS -0.04
- Stochastic Oscillator
- TALK 44.64
- XERS 11.32
About TALK Talkspace Inc.
Talkspace Inc is a behavioral healthcare company offering access to licensed therapists, psychologists, and psychiatrists through its technology platform. It serves clients including health plans, enterprises, and individual subscribers. Therapists address various mental health conditions, while psychiatrists cater to a higher acuity demographic. Revenue primarily stems from payor and direct-to-enterprise clients, with contracts lasting one to three years. The majority of the Company's operations and revenues are based in the United States.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.